ArticleScientific reports2025
The extent of alpha-synuclein aggregate accumulation in neurons varies depending on the type of neurotransmitter they release.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The Role of DaT-SPECT Imaging in the Evaluation of Progressive Supranuclear Palsy.Life (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alpha-synuclein (aSyn) is a highly conserved 140-amino acid presynaptic protein involved in neuronal plasticity and recognized as the pathogenic protein in Parkinson's disease. Aggregated aSyn propagates transsynaptically between neurons in vivo, impairing the cellular function of affected cells. However, it remains unclear whether aggregated aSyn propagates similarly across all neuronal cell types. In this study, we injected sonicated aSyn preformed fibrils into the striatum of mice and used immunohistochemistry to observe the intracellular localization of aSyn aggregates at designated survival times. Four weeks post-injection, numerous filamentous aggregates were detected in the striatum, neocortex, and substantia nigra. Multiple immunostaining techniques with neuronal markers, combined with electron microscopy, revealed that some filamentous aggregates accumulated in the perinuclear cytoplasm of neurons in these regions. However, quantitative analyses revealed that the number of cell bodies containing aSyn aggregates in the striatum was significantly lower than that in the neocortex or substantia nigra. Additionally, we examined aSyn aggregates in the glial cells of the striatum and found that filamentous aggregates were rarely detected, even 16 weeks post-injection. These findings suggest a cell-type preference depending on neurotransmitter identity for aSyn aggregation and propagation in vivo.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.